NDAORAL-28TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLESTRIN FE 1/50 is an oral contraceptive combining norethindrone acetate (progestin), ethinyl estradiol (estrogen), and ferrous fumarate (iron supplement) in a 28-day tablet regimen. It prevents pregnancy through hormonal suppression of ovulation and is indicated for contraception in women of childbearing potential. The iron component addresses menstrual blood loss-related anemia, a common side effect of hormonal contraceptives.
Pre-Launch
As a pre-launch product, teams are focused on market entry strategy, payer negotiations, and launch readiness; commercial headcount will scale post-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORLESTRIN FE 1/50 offers entry or mid-career professionals exposure to a high-volume, consumer-facing therapeutic area with established market dynamics and complex payer landscapes. Pre-launch timing provides unique opportunity to shape commercial strategy, payer messaging, and market positioning from inception.
Brand ManagerMedical Science Liaison
Worked on NORLESTRIN FE 1/50 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.